BAVA Bavarian Nordic A/S

Rumours of a Potential Takeover Offer for Bavarian Nordic A/S

Rumours of a Potential Takeover Offer for Bavarian Nordic A/S

COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a consortium consisting of Nordic Capital and Permira.

Bavarian Nordic A/S can confirm that we have been in discussions with Nordic Capital and Permira regarding a potential takeover offer for Bavarian Nordic A/S by Nordic Capital and Permira.

As these discussions are continuing, there can be no certainty as to whether any offer for Bavarian Nordic A/S by Nordic Capital and Permira will be made, or the timing or the terms of such offer.

Bavarian Nordic A/S has no further comments to make at this stage and refers to its normal procedure for the prompt provision of information to the financial market. Further information will be announced when required.

About Bavarian Nordic

Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:

Europe: Rolf Sass Sørensen, Vice President Investor Relations, , Tel:

US: Graham Morrell, Gilmartin Group, , Tel:

Contact media:

Nicole Seroff, Vice President Corporate Communications, , Tel:

Company Announcement no. 20 / 2025

Vedhæftet fil



EN
24/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE

Rumours of a Potential Takeover Offer for Bavarian Nordic A/S

Rumours of a Potential Takeover Offer for Bavarian Nordic A/S COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a consortium consisting of Nordic Capital and Permira. Bavarian Nordic A/S can confirm that we have been in discussions with Nordic Capital and Permira regarding a potential takeover offer for Bavarian Nordic A/S by Nordic Capital and Permira. As these discussions are continuing, there can be no certainty as to whether any offer for Bavarian Nordic A/S by Nordic ...

 PRESS RELEASE

Rumours of a Potential Takeover Offer for Bavarian Nordic A/S

Rumours of a Potential Takeover Offer for Bavarian Nordic A/S COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a consortium consisting of Nordic Capital and Permira. Bavarian Nordic A/S can confirm that we have been in discussions with Nordic Capital and Permira regarding a potential takeover offer for Bavarian Nordic A/S by Nordic Capital and Permira. As these discussions are continuing, there can be no certainty as to whether any offer for Bavarian Nordic A/S by Nordic ...

 PRESS RELEASE

Bavarian Nordics ansøgning om markedsføringstilladelse for chikungunya...

Bavarian Nordics ansøgning om markedsføringstilladelse for chikungunyavaccinen er blevet accepteret til gennemgang af de canadiske lægemiddelmyndigheder KØBENHAVN, Danmark, 22. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at de canadiske lægemiddelmyndigheder, Health Canada, har accepteret selskabets ansøgning om markedsføringstilladelse for den virus-lignende partikel (VLP)-baserede, enkelt-dosis chikungunyavaccinekandidat, CHIKV VLP, til forebyggelse af sygdom forårsaget af chikungunyavirus hos personer på 12 år og ældre. Dermed starter myndighedernes standardgenne...

 PRESS RELEASE

Bavarian Nordic Receives Acceptance from Health Canada for Review of t...

Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is comp...

 PRESS RELEASE

Bavarian Nordic modtager ny ordre på koppe-/mpoxvacciner fra europæisk...

Bavarian Nordic modtager ny ordre på koppe-/mpoxvacciner fra europæisk land Gentagen ordre fra unavngivet europæisk land til styrkelse af det offentlige beredskab.Sammen med andre nylige ordrer fra ikke-europæiske lande har selskabet nu sikret kontrakter for mere end DKK 3.000 mio. i Public Preparedness-forretningen i 2025, og rammer dermed det forventede interval for dette forretningsområde. KØBENHAVN, Danmark, 9. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har modtaget en kontrakt til en værdi på over DKK 200 mio. på levering af MVA-BN® koppe-/mpoxvaccine ti...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch